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This report describes one case of verified treatment 
failure of pharyngeal gonorrhoea using ceftriaxone in 
Sweden. Previous reports described verified treatment 
failure of urogenital gonorrhoea using the internation-
ally  recommended  first-line  drug  cefixime,  but  not 
with ceftriaxone, the last remaining option for empiri-
cal treatment of gonorrhoea. Enhanced awareness of 
clinical  failures,  pharmacodynamic  considerations, 
follow-up and test of cure, adherence to appropriate 
case  management  and  treatment  guidelines  as  well 
as verification/falsification of presumed clinical treat-
ment failures should be emphasised worldwide.
Case report 
In late July 2010, a Swedish heterosexual man in his early 
20s presented to a primary healthcare clinic in Sweden 
(on day 1) with symptoms and signs of urogenital and 
pharyngeal infection (Table). Four days earlier he had 
had protected vaginal intercourse and unprotected oral 
sex with a casual female partner in Japan. Polymerase 
chain reaction (PCR) analysis of DNA obtained from his 
urine  sample  was  positive  for  Neisseria  gonorrhoeae 
(using Cobas 4800 PCR, Roche Molecular Systems). He 
was  given  out-of-date  empirical  treatment  for  gonor-
rhoea (amoxicillin) and referred to a clinic for sexual 
transmitted infections. On day 12, he presented to this 
clinic with resolved urogenital symptoms, but pharyn-
geal inflammation was still present. Although micros-
copy, culture and PCR analysis of urogenital samples 
were  negative  for  N.  gonorrhoeae,  a  pharyngeal  cul-
ture was N. gonorrhoeae positive and he was therefore 
given (day 26) ceftriaxone (250 mg), an extended-spec-
trum cephalosporin (ESC), which is an internationally 
recommended first-line treatment for gonorrhoea. On 
day 36, follow-up examination and test of cure showed 
that the pharyngeal culture remained positive, the pha-
ryngeal inflammation persisted, and he was given 500 
mg ceftriaxone on day 43. On day 50, he returned with 
persisting positive pharyngeal culture and pharyngeal 
inflammation. He was subsequently administered one 
dose of 1 g ceftriaxone intraveneously (on day 71) and 
was also referred to an otorhinolaryngologist, who did 
not identify any pharyngeal abnormalities. On days 85 
and 92, two follow-up examinations showed no visible 
signs  of  infection  and  two  pharyngeal  cultures  were 
negative for N. gonorrhoeae. The patient reported no 
sexual contacts from day one until the N. gonorrhoeae 
culture results were negative (Table). 
Characterisation of N. gonorrhoeae 
isolates (before and after treatment)
All N. gonorrhoeae isolates were species-confirmed by 
sugar  utilisation  test  and  Phadebact  Monoclonal  GC 
Test (Pharmacia Diagnostics). 
All  pre-  and  post-treatment  isolates  were  indistin-
guishable  using  serovar  determination  (Bpyvut),  full-
length  DNA  sequencing  of  the  N.  gonorrhoeae  porB 
gene,  and  N.  gonorrhoeae  multiantigen  sequence 
typing  (NG-MAST;  ST2958),  performed  as  previously 
described  [1].  Using  Etest  (AB  bioMérieux,  Sweden), 
all  isolates  displayed  a  ceftriaxone  minimum  inhibi-
tory concentration (MIC) of 0.125 or 0.25 mg/L (Table), 
and overall indistinguishable antibiograms (ampicillin 
2  mg/L,  cefixime  0.5  mg/L,  spectinomycin  12  mg/L, 
azithromycin  0.5  mg/L,  ciprofloxacin  >32  mg/L,  gen-
tamicin  4  mg/L)  and  were  beta-lactamase  negative. 
According to the ceftriaxone breakpoints stated by the 
European  Committee  on  Antimicrobial  Susceptibility 
Testing  (EUCAST)  [2],  the  ceftriaxone  MICs  of  these 
isolates  were  equal  to  or  slightly  above  the  resist-
ance  breakpoint  (>0.125  mg/L).  Sequencing  of  the 
N. gonorrhoeae penA, mtrR and porB1b alleles, which 
are known to contribute to the resistance to ESCs, was 
performed as previously described [3]. All isolates con-
tained an identical penA mosaic allele that has been 
correlated  with  treatment  failure  using  oral  ESCs  in 
Japan and recently in Norway [4-6], and had mtrR and 
penB  alterations  that  enhance  further  the  ESC  MIC 
[7,8]. 
Background
Gonorrhoea  remains  a  public  health  concern  glo-
bally. N. gonorrhoeae has developed resistance to all 2 www.eurosurveillance.org
antimicrobials previously used as first-line treatments 
[4]. Furthermore, susceptibility to the currently inter-
nationally  recommended  first-line  ESCs  that  are  the 
last remaining treatment options – cefixime (oral) and 
ceftriaxone (injectable) – has rapidly decreased world-
wide  [4].  Verified  treatment  failures  using  cefixime 
have already been reported from Japan [5] and recently 
also from Europe [6]. Treatment failures of urogenital 
gonorrhoea using ceftriaxone have still not been veri-
fied, but two cases of clinical failure in the treatment of 
pharyngeal gonorrhoea were reported in Australia [9]. 
However, as the ceftriaxone MICs of these gonococcal 
isolates were low (0.016 and 0.032 mg/L), these clini-
cal failures were unlikely to have been due to bacterial 
resistance. Rather it was probably due to the known 
difficulties  in  treating  pharyngeal  gonorrhoea  com-
pared  with  urogenital  infection.  Due  to  pharmacody-
namic parameters, few antimicrobial drugs can reliably 
cure more than 90% of pharyngeal gonorrhoea infec-
tions  [4,10-12].  Worryingly,  the  first  N.  gonorrhoeae 
strain displaying high-level ceftriaxone resistance has 
now been isolated in Japan [13].   
Discussion and conclusion
This  study  describes  one  case  of  clinical  failure  of 
pharyngeal  gonorrhoea  using  internationally  recom-
mended first-line treatment ceftriaxone, which is the 
last remaining treatment option. The treatment failure 
was rigorously confirmed in accordance with the World 
Health Organization (WHO) recommendations [4], i.e. 
a detailed clinical history was recorded and the likeli-
hood of re-exposure and reinfection was excluded as 
much  as  possible.  Accordingly,  the  patient  reported 
no sexual contact after his initial one in Japan (place 
of exposure) and the gonococcal sequence type iden-
tified,  ST2958,  has  previously  been  found  only  in 
Australia  [14].  Furthermore,  pre-  and  post-treatment 
isolates were phenotypically and genetically indistin-
guishable using highly discriminatory genetic epidemi-
ological typing, MICs of ceftriaxone were substantially 
enhanced, and the isolates contained resistance deter-
minants causing enhanced ceftriaxone MICs.
We  may  now  be  reaching  the  ceftriaxone  MICs  for 
which complete bacterial eradication in pharynx, and 
soon in the urogenital tract, will be impossible in rare 
cases.  According  to  Monte  Carlo  simulations  [15],  a 
250 mg dose of ceftriaxone results in median times of 
free ceftriaxone above the MIC (fT>MIC) of only 24.1 h 
(range: 10.5–52.2 h) and 15.4 h (range: 5.3–34.3 h) for 
the MICs of 0.125 mg/L and 0.25 mg/L, respectively, 
which were detected in the present study. Such ceftri-
axone MICs may cause rare treatment failures, which 
most likely will be more frequent when treating pha-
ryngeal gonorrhoea, for which the fT>MIC of accessible 
ceftriaxone will be even shorter. Such treatment fail-
ures  may  already  be  occurring  but  not  being  identi-
fied due to rare use of test of cure and also because 
Table 
Details of verified clinical failure of one case of Neisseria gonorrhoeae pharyngeal infection using internationally 
recommended first-line ceftriaxone treatment of gonorrhoea, Sweden, 2010
Type of healthcare 
clinic (day of 
presentation)
Symptoms  
(signs)
Diagnostic test MIC (mg/L)a
NG-MASTb Treatment 
(day administered) Positive 
(type of sample)
Negative 
(type of sample) Ampicillin Ceftriaxone
Primary (1)
Urethral dis-
charge, dysuria, 
pharyngeal pain
(inflammation 
in urethra and 
pharynx)
PCR 
(urine) NA NA NA NA
Amoxicillin 
Two daily doses of 750 mg, 
for 10 days, 
oral administration 
(first administered on day 1)
STI (12)
– 
(inflammation in 
pharynx)
Culture 
(pharyngeal)
Microscopy and 
culture 
(urethral) 
PCR (urine)
2 0.125 ST2958
Ceftriaxone 
One dose of 250 mg, 
intramuscular administration 
(day 26)
STI (36)
– 
(inflammation in 
pharynx)
Culture 
(pharyngeal) NA 2 0.125 ST2958
Ceftriaxone 
One dose of 500 mg, 
intramuscular administration 
(day 43) 
STI (50)
–  
(inflammation in 
pharynx)c
Culture 
(pharyngeal) NA 2 0.25 ST2958
Ceftriaxone 
One dose of 1 g, 
intravenous administration 
(day 71)
STI (85 and 92)
–
(–)
NA Culture 
(pharyngeal) NA NA NA NA
MIC: minimum inhibitory concentration; NA: not applicable; PCR: polymerase chain reaction; STI: sexually transmitted infections. 
a Etest was used and all MIC values were rounded up to whole MIC dilutions.
b Neisseria gonorrhoeae multiantigen sequence typing of cultured N. gonorrhoeae post-treatment isolates.
c The patient was also referred to an otorhinolaryngologist, who did not identify any pharyngeal abnormalities. 3 www.eurosurveillance.org
azithromycin [16] is administered to many gonorrhoea 
patients, due to suspicion of concomitant chlamydial 
infection [4,15].
Notably, the current case presented initially to a pri-
mary healthcare clinic with urogenital and pharyngeal 
symptoms. Despite the pharyngeal pain, however, no 
pharyngeal sample was taken and, in addition, he was 
given out-of-date treatment. It is therefore crucial that 
national  case  management  and  treatment  guidelines 
are up to date and strictly adhered to at all levels of 
the healthcare system, including at the primary level.  
In conclusion, one case of clinical failure using stand-
ard ceftriaxone treatment for pharyngeal gonorrhoea 
has  been  verified  in  Sweden.  An  increased  aware-
ness of future clinical failures (including those using 
ceftriaxone),  more  frequent  test  of  cure,  and  strict 
adherence to appropriate case management and treat-
ment guidelines as well as verification/falsification of 
presumed  treatment  failures  should  be  emphasised 
worldwide. Importantly, treatment of pharyngeal gon-
orrhoea poses a considerable challenge as it is harder 
to treat than urogenital infection, is frequently asymp-
tomatic and acts as a reservoir for infection and emer-
gence of resistance [4]. Accordingly, it is important not 
only to collect information regarding clinical anamne-
sis, but also on patients’ sexual practices and, if indi-
cated, subsequently take extragenital samples as well. 
Finally, there is a need for studies on the pharmacoki-
netics/pharmacodynamics  of  antimicrobial  drugs  in 
the pharynx, and new treatment options (single or in 
combination) as well as new drug development for gon-
orrhoea treatment.
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